📰 Code Therapeutics News
Page 3 - Code Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Code Therapeutics. Real-time updates on events, politics, business and more.
January 17, 2024
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.
January 13, 2024
By Denny Jacob TransCode Therapeutics said Michael Dudley, co-founder and chief executive, would retire, part of its restructuring intended to further reduce...
January 12, 2024
By Denny Jacob TransCode Therapeutics said Michael Dudley, co-founder and chief executive officer, would retire, as part of its previously disclosed...
January 12, 2024
BOSTON, Jan. 12, 2024 -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its...
January 4, 2024
An Open Letter to Shareholders of TransCode Therapeutics, Inc....
January 2, 2024
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 437,500 shares, a decline of 31.3% from the November 30th total of 637,200 shares. Currently, 2.0% of the shares of the stock are […]
January 1, 2024
HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock. TransCode Therapeutics Stock Performance TransCode Therapeutics stock opened at $1.78 on Wednesday. TransCode Therapeutics has a 52-week low of $0.42 […]
January 1, 2024
HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a $3.00 target price on the stock. TransCode Therapeutics Stock Performance NASDAQ:RNAZ opened at $1.78 on Wednesday. The firm has a market cap of $11.75 million, a […]
December 5, 2023
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that
November 30, 2023
BOSTON, Nov. 30, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a...